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Background: New criteria for the diagnosis and classification of chronic graft-versus-host disease
were developed in 2005 for the purpose of clinical trials with a consensus sponsored by the National
Institute of Health.
Objectives: The aim of this study is to present the results of a multicenter pilot study performed by the
Brazil-Seattle chronic graft-versus-host disease consortium to determine the feasibility of using these
criteria in five Brazilian centers.
Methods: The study was performed after translation of the consensus criteria into Portuguese and
training. A total of 34 patients with National Institute of Health chronic graft-versus-host disease were
enrolled in the pilot study between June 2006 and May 2009.
Results: Of the 34 patients, 26 (76%) met the criteria of overlap syndrome and eight (24%) the classic
subcategory. The overall severity of disease was moderate in 21 (62%) and severe in 13 (38%)
patients. The median time from transplant to onset of chronic graft-versus-host disease was 5.9
months (Range: 3 - 16 months); the median time for the overlap syndrome subcategory was 5.9
months (Range: 3 - 10 months) and for the classic subcategory, it was 7.3 months (Range: 3 - 16
months). At a median follow up of 16.5 months (Range: 4 - 39 months), overall survival was 75%.
Conclusions: It was feasible to use the National Institute of Health consensus criteria for the diagnosis
and scoring of chronic graft-versus-host disease in a Brazilian prospective multicenter study. More
importantly, a collaborative hematopoietic cell transplantation network was established in Brazil
offering new opportunities for future clinical trials in chronic graft-versus-host disease and in other
areas of research involving hematopoietic stem cell transplantation.
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Introduction
Chronic graft-versus-host disease (GvHD) remains an elusive disorder to characterize
and represents the major cause of morbidity and mortality affecting long-term survivors of
allogeneic hematopoietic stem cell transplantation (HSCT).(1-4)
Approximately 50% of patients develop chronic GvHD. The rate varies between 6%
to 80% depending on several factors including recipient and donor ages, prior acute GvHD,
donor type, patient/recipient gender mismatch, stem cell source, graft manipulation, use of
post-transplantation donor lymphocyte infusions (DLI) and the clinical diagnosis criteria
used.(5-8) This immunologic complication after allogeneic HSCT resembles an autoimmune
disease with clinical manifestations of collagen vascular diseases, such as oral ulcerations
(lichen planus), keratoconjunctivitis sicca, xerostomia, polyserositis, esophagitis and
stricture, vaginal ulceration and stricture, intrahepatic obstructive liver disease, obstructive
pulmonary disease, scleroderma, morphea, fasciitis and myositis.(2,4,9) These manifestations
are associated with debilitating consequences, such as reduced quality of life, impaired
functional status, need for extended immune suppression, profound chronic immune
suppression leading to recurrent or life-threatening infections and death.(1,10-17)
The historical classification of chronic GvHD proposed in 1980 included limited disease
(i.e., only localized skin and/or liver involvement) and extensive disease (i.e., generalized
skin or limited disease plus involvement of other organs).(9) In 2001, the classification was
revised to distinguish patients who required systemic immune suppression from those
who did not.(3) Although highly reproducible among transplant centers, the Seattle revised
chronic GvHD criteria did not stratify patients according to outcomes.(18,19)
Unlike other innovations in HSCT, progress in chronic GvHD has been slow due to
the variability of the clinical manifestations of this syndrome, the lack of consistent
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diagnostic laboratory findings, the limited understanding of
its pathogenesis and the slow accrual of patients in clinical
trials.(20-22) In the last 6 years however, the growing interest in
chronic GvHD research has been spurred by the National
Institute of Health (NIH) sponsored consensus project in
chronic GvHD that included six working groups of
multidisciplinary experts on diagnosis and staging,
histopathology, biomarkers, response criteria, supportive care
and design of clinical trials. Each of the six working groups
presented their reports at the June 2005 NIH Consensus
Meeting on critical issues for future research in chronic
GvHD.(20) Recommendations for future clinical trials by each
of the NIH consensus working groups have been published
based on experts' opinion due to insufficient data at the time
to provide evidence-based recommendations.(23-28)
In an effort to foster collaboration and expand the
network for future clinical trials in chronic GvHD, a Brazil-
Seattle consortium was established between HSCT
investigators from the Fred Hutchinson Cancer Research
Center (FHCRC) and from five Brazilian institutions. The
current manuscript describes the establishment of the Seattle-
Brazil consortium as a platform to conduct future collaborative
studies in chronic GvHD and other HSCT areas and presents
the results of the first 34 patients enrolled in a pilot study to
determine the feasibility of conducting a multicenter,
prospective, observational clinical trial in chronic GvHD using
the NIH criteria(23) in five Brazilian institutions between June
2006 and May 2009.
Methods
The consortium
The Brazil-Seattle consortium was established in 2008
by a Brazilian-American expert in chronic GvHD and other
late effects of HSCT at the FHCRC in Seattle and by
investigators with common research interests from five
Brazilian institutions (Universidade Estadual de Campinas,
Instituto Nacional de Câncer in Rio de Janeiro, Universidade
Federal do Rio de Janeiro, Universidade Federal do Paraná in
Curitiba and Hospital Amaral Carvalho in Jaú). The objective
of the consortium was to establish a platform to conduct
future collaborative studies in chronic GvHD and other
research areas in HSCT between investigators in Brazil and
Seattle. The consortium consists of a multidisciplinary team
of HSCT physicians, one dermatologist, dentists,
psychiatrists, psychologists, physiotherapists and two data
managers. Medical training was conducted at the FHCRC for
most of the physicians and one dentist, and was extended to
others members of the teams in Brazil.
The consortium held monthly teleconferences with
investigators from Brazil and Seattle and met at least twice
yearly during annual meetings of the American and the
Brazilian Societies of HSCT and Hematology. After
completion of the chronic GvHD training and translation to
Portuguese of the NIH consensus criteria, a pilot study to
determine the feasibility of conducting a multicenter,
prospective, observational clinical trial in chronic GvHD was
initiated by the consortium upon approval of the institutional
review boards of each of the five participating centers.
Inclusion criteria and definitions
The inclusion criteria were over 2-year-old patients with
a diagnosis of chronic GvHD by NIH criteria(23) that required
systemic immunosuppression treatment and who were within
the first 3 years of their allogeneic HSCT. Only patients with
no evidence of primary disease relapse/progression after
transplantation were included, although the presence of
minimal residual disease by molecular testing was allowed.
Patients with an inability to comply with study procedures or
anticipated survival of less than 6 months due to co-morbid
disease were excluded. The criteria for diagnosis and staging
of chronic GvHD were according to the 2005 NIH consensus
recommendations for clinical trials.(23)
Patients enrolled in the study within 3 months from the
initial diagnosis of chronic GvHD were categorized as 'incidence
cases' and those enrolled after 3 months from the initial
diagnosis of chronic GvHD were classified as 'prevalent cases'.
When patients received only topical therapy at the initial
diagnosis of chronic GvHD, but subsequently required
systemic treatment and then enrolled in the study, they were
classified as incident or prevalent cases according to the date
of the initial diagnosis of chronic GvHD and not the date when
treatment with systemic immunosuppression was started.
Study procedure
No therapeutic intervention was indicated by this study.
Appropriate patients were identified by individual physicians
at each center at the time of clinical visits. Potentially eligible
patients were approached and the study procedures outlined.
Signed informed consent was required for study enrollment.
The patients were registered at the local institution. They
were assigned a unique sequential study identification
number after verification of eligibility and receipt of informed
consent. Each institution retained a file of the patients enrolled
in the study.
Patients were evaluated at the time of study enrollment
and at 6-month intervals. Newly diagnosed patients (incident
cases) had an additional assessment 3 months after enrollment.
Physicians provided standardized information about organ
involvement and symptoms at each evaluation. Only
enrollment data were analyzed in the pilot study.
The medical assessment included the NIH chronic GvHD
diagnosis and staging consensus,(20,23) as well the Hopkins
and Vienna(29) scoring systems. Data were collected on skin,
mouth, eye, gastrointestinal, liver and lung involvement, overall
severity ratings (mild, moderate and severe), and perceptions
of changes by physicians. As the mouth is the most common
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site of NIH chronic GvHD symptoms,(21) an oral cavity diagram
was included in our study (Figure 1) to help to estimate the
percentage of oral cavity surface involvement when grading
GvHD. The length and width of the largest oral ulcer was also
added to monitor response.
Statistical analysis
The objective of this multicenter, prospective,
observational pilot study was to determine its feasibility of
using the diagnosis and staging of chronic GvHD according
to the NIH criteria at five institutions in Brazil. Each
participating institution collected data prospectively.
Demographic and transplant related information were
calculated as proportions. The comparison between groups
was performed using chi-squared tests. Overall survival after
onset of chronic GvHD was estimated by the Kaplan-Meier
method. Analysis was carried out as of December 2009.
Results
The Brazil-Seattle chronic GvHD multidisciplinary
study group (GeDECH-Brasil/Seattle) was conceived by
several Brazilian investigators who had been post-doctor
fellows or visiting physicians at the FHCRC and by Mary
Flowers, a collaborator and mentor in Seattle. The first
initiative of the GeDECH-Brasil-Seattle consortium was to
conduct a feasibility, multicenter, prospective, observational
pilot study in a chronic GvHD Brazilian population applying
NIH criteria similar to those being tested in a larger multicenter
observational chronic GvHD study in the United States by
Stephanie Lee et al. since 2007.
A total of 34 patients were enrolled in this pilot study.
At least 5 patients were enrolled from each of the five
participating institutions with the first patient enrolled in
March 2008 and the last one in September 2009.
Patient and transplant characteristics are shown in Table
1.  The median patient age was 36 years old (range: 15 - 65
years) and 67% (n = 23) were male. The majority of patients
(94%) had HLA matched related donors (n=32) and most
(91%) received a high-dose pre-transplant conditioning
regimen with chemotherapy but without total body irradiation
(n = 31). The source of stem cells for the HSCT was peripheral
blood in 21 patients (64%). Twenty patients (59%) received
their first allogeneic HSCT between 2008 and 2009 and 14
patients (41%) between 2006 and 2007.
Chronic GvHD characteristics are shown in Table 2.
The median time from HSCT to diagnosis of chronic GvHD
Figure 1 – Oral assessment
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was 5.9 months (range: 3 - 16 months) and from initial
diagnosis of chronic GvHD to enrollment was 2.2 months
(range: 0.4 - 15 months).
Of the 34 patients, 24 (71%) were incident cases and 10
(29%) prevalent cases. Twenty-six (76%) patients met the
NIH chronic GvHD subcategory of overlap syndrome and 8
(24%) the classic subcategory. The median time from
transplant to chronic GvHD was shorter for overlap syndrome
at 5.9 months (range: 3 - 10 months) compared to 7.3 months
(range: 3 - 16 months) for the classic subcategory. Among
the 34 patients, 4 (12%) had one organ/site involvement, 11
(32%) had two organ/site involvement, 11 (32%) had three
organ/site involvement and 8 (24%) had four or more organ/
site involvement at the time of study enrollment. The organs/
sites involved by chronic GvHD at initial diagnosis are shown
in Figure 2.
Overall, 21/34 (62%) patients had no prior history of
grade 2-4 acute GvHD with 5 of 8 (62%) in the classic and 16
of 26 (47%) in overlap chronic GvHD subcategories. Of the
13/34 (38%) patients with prior grade 2-4 acute GvHD, 10/26
Figure 2 – Percentage of site/organs involved by chronic GvHD at
diagnosis
(38%) belonged to the overlap chronic GvHD subcategory
and 3/8 (38%) to the classic subtype. The distribution of
patients with and without prior acute GvHD was not
statistically significant between the chronic GvHD
subcategories.
Most patients (21/34; 62%) had de novo onset of
chronic GvHD, 15 in the overlap and 6 in the classic
subcategories. No statistically significant differences
between type of onset and NIH chronic GvHD subcategories
were found (p-value = 0.17) (Figure 3).
The frequency of selected high risk features at the time
of initial diagnosis of chronic GvHD associated with poor
survival or prolonged immunosuppression(1,5,17,28) are shown
in Table 2. At the time of initial diagnosis, 7 patients (20%)
had progressive onset of chronic GvHD, 5 patients (15%)
had platelet counts below 100 x 109/L, 10 patients (29%) had
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skin involvement of more than 50% of the total body surface
area and 17 patients (50%) were receiving corticosteroids at
a dose equal to or greater than 0.5 mg/kg/day.
The severity of chronic GvHD in the cohort studied is
shown in Figure 4. Overall, the severity of chronic GvHD was
graded as moderate in 21/34 (62%) and severe in 13/34 (38%)
patients. Among the 21 patients with moderate disease, 16
were in the overlap and 5 in the classic chronic GvHD
subcategories. Of the 13 patients with severe disease, 10
were in the overlap and 3 in the classic chronic GvHD groups.
There was no significant statistical difference between
moderate and severe disease between the subcategories
(p-value = 0.64).
After a median follow-up of 16.5 months, the overall
survival from the initial chronic GvHD diagnosis in our patient
population was 75% (Figure 5).
Discussion
Two points should be highlighted in this paper. The
first relates to describing the establishment of a consortium
between investigators at the FHCRC and at Brazilian
institutions to promote collaboration in research areas of
common interest in HSCT, such as the Brazil-Seattle chronic
GvHD multidisciplinary study group. The second relates to
reporting the feasibility of conducting a multicenter pilot
observational study in chronic GvHD applying the diagnostic,
staging and response criteria as recommended by the 2005
NIH consensus conference for clinical trials.
In this pilot study we describe the characteristics of
patients with NIH defined chronic GvHD who met the overlap
syndrome and classic subcategories. The most prevalent
subcategory of chronic GvHD observed was the overlap
syndrome (76%), a result similar to that reported in a large
North American retrospective study(30) but different to others
reports.(31-33) Most patients in our study had de novo onset
of chronic GvHD (i.e., no prior acute GvHD) equally
distributed among patients in the overlap and classic chronic
GvHD subcategories. The majority of patients had 2 or 3
organs/sites involved with the mouth being the most
prevalent site (91%), thus corroborating with previous
findings.(21) Similar to other studies,(31,32) the overall severity
of chronic GvHD of most patients in our study cohort was
moderate in both overlap syndrome and classic chronic GvHD
subcategories.
Presence of high risks features associated with poor
survival at the initial diagnosis of chronic GvHD (i.e.,
thrombocytopenia, progressive onset of chronic GvHD and
skin involvement of more than 50% of the body surface area)
was observed in approximately one third of patients in our
study. While the follow-up is short, the 75% overall survival
is an encouraging observation.
Several retrospective studies on evaluating the NIH
criteria by assessing outcomes among patients with
historically defined chronic GvHD reported conflicting
Figure 3 – Chronic GvHD subcategories according to type of onset
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Figure 4 – Overall severity of chronic GvHD at study enrollment
Figure 5 – Overall survival from initial diagnosis using NIH chronic
GvHD criteria
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results.(30-35) In a large retrospective study evaluating the NIH
consensus criteria in the classification of late acute and
chronic GvHD, Vigorito et al.(30) reported that antecedent late
acute GvHD was associated with an increased risk of non-
relapse mortality and prolonged treatment in patients with
NIH chronic GvHD. In that study, however, there was no
statistically significant association between the presence or
absence of NIH chronic GvHD criteria with survival, risk
factors or non-relapse mortality, recurrent malignancy, or
duration of systemic treatment.(30) In two smaller studies,
however, Jagasia et al.(31) and Arora et al.(32) reported lower
survival among patients with NIH GvHD defined as late,
persistent, recurrent and acute compared to patients in
overlap syndrome or classic chronic GvHD subcategories.
In another study evaluating the NIH GvHD criteria, Cho et
al.(33) reported no significant differences in GvHD-specific
survival according to the NIH GvHD diagnostic criteria.  Pérez-
Simón et al.,(34) Kim et al.(35) and other investigators(32,33)
evaluated the overall severity of chronic GvHD according to
NIH criteria as a risk factor for survival and non-relapsed
mortality and reported a lower survival for patients graded as
severe.
The discrepant results of the above studies may be
explained by differences in the historical criteria used to
make the diagnosis of chronic GvHD and by inadequacies
in documenting the presence or absence of the diagnostic
and distinctive manifestations of chronic GvHD necessary
to categorize patients by the NIH consensus criteria.
Considering the previously inconsistent results(30-35) and
that late acute GvHD by NIH criteria represents a
subcategory of the historical chronic GvHD diagnosis,(3,23)
with proper stratification, patients with late acute GvHD
should be included in clinical trials for chronic GvHD.
When analyzing chronic GvHD as an outcome of HSCT,
the capture of both late acute and chronic GvHD by the
2005 NIH criteria is important, since failing to do so will
likely underestimate the incidence of chronic GvHD and
lead to misinterpretation of results when this outcome is
compared with prior studies using the historical chronic
GvHD criteria.(3,23)
In conclusion, this pilot study demonstrates the
feasibility of applying the NIH consensus criteria for the
diagnosis and scoring of chronic GvHD in a multicenter
prospective study at five Brazilian institutions and, more
importantly, in establishing a consortium of investigators
interested in new opportunities to collaborate in future
intervention, validation, and biomarker clinical trials in chronic
GvHD and other areas of common research interest in
hematopoietic stem cell transplantation.
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